Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention

TY - JOUR

T1 - Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention

AU - Campo, Gianluca

AU - Pavasini, Rita

AU - Morciano, Giampaolo

AU - Lincoff, Michael A

AU - C Gibson, Michael

AU - Kitakaze, Masafumi

AU - Lonborg, Jacob

AU - Ahluwalia, Amrita

AU - Ishii, Hideki

AU - Frenneaux, Michael

AU - Ovize, Michel

AU - Galvani, Marcello

AU - Atar, Dan

AU - Ibanez, Borja

AU - Cerisano, Giampaolo

AU - Biscaglia, Simone

AU - Neil, Brandon J

AU - Asakura, Masanori

AU - Engstrom, Thomas

AU - Jones, Daniel A

AU - Dawson, Dana

AU - Ferrari, Roberto

AU - Pinton, Paolo

AU - Ottani, Filippo

PY - 2017/10

Y1 - 2017/10

N2 - Mortality and morbidity in patients with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) are still high [1]. A huge amount of the myocardial damage is related to the mitochondrial events happening during reperfusion [2]. Several drugs directly and indirectly targeting mitochondria have been administered at the time of the PCI and their effect on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal (hospital readmission for heart failure (HF)) outcomes have been tested showing conflicting results [3–16]. Data from 15 trials have been pooled with the aim to analyze the effect of drug administration versus placebo on outcome [17]. Subgroup analysis are here analyzed: considering only randomized clinical trial (RCT) on cyclosporine or nicorandil [3–5,9–11], excluding a trial on metoprolol [12] and comparing trial with follow-up length <12 months versus those with longer follow-up [3–16]. This article describes data related article titled “Clinical Benefit of Drugs Targeting Mitochondrial Function as an Adjunct to Reperfusion in ST-segment Elevation Myocardial Infarction: a Meta-Analysis of Randomized Clinical Trials” [17].

AB - Mortality and morbidity in patients with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) are still high [1]. A huge amount of the myocardial damage is related to the mitochondrial events happening during reperfusion [2]. Several drugs directly and indirectly targeting mitochondria have been administered at the time of the PCI and their effect on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal (hospital readmission for heart failure (HF)) outcomes have been tested showing conflicting results [3–16]. Data from 15 trials have been pooled with the aim to analyze the effect of drug administration versus placebo on outcome [17]. Subgroup analysis are here analyzed: considering only randomized clinical trial (RCT) on cyclosporine or nicorandil [3–5,9–11], excluding a trial on metoprolol [12] and comparing trial with follow-up length <12 months versus those with longer follow-up [3–16]. This article describes data related article titled “Clinical Benefit of Drugs Targeting Mitochondrial Function as an Adjunct to Reperfusion in ST-segment Elevation Myocardial Infarction: a Meta-Analysis of Randomized Clinical Trials” [17].

U2 - 10.1016/j.dib.2017.07.033

DO - 10.1016/j.dib.2017.07.033

M3 - Journal article

C2 - 28795098

SN - 2352-3409

VL - 14

SP - 197

EP - 205

JO - Data in Brief

JF - Data in Brief

ER -